X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of CTX112, which is an investigational allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy for the treatment of CD19+ malignancies and autoimmune diseases.
Lead Product(s): CTX112
Therapeutic Area: Oncology Product Name: CTX112
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $280.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 13, 2024
Details:
Casgevy (exagamglogene autotemcel) is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Exa-cel, formerly known as CTX001™, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with SCD or TDT.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: Casgevy
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
Exa-cel (exagamglogene autotemcel), formerly known as CTX001, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with sickle cell disease.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Exa-cel, formerly known as CTX001™, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with SCD or TDT.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Exa-cel, formerly known as CTX001™, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with SCD or TDT.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Exa-cel, formerly known as CTX001™, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with SCD or TDT.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Hematology Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Vertex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Under the agreement, Vertex will receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D and generating fully differentiated, insulin-producing hypoimmune islet cells for T1D.
Lead Product(s): Insulin-producing Hypoimmune Islet Cells
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $330.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement March 27, 2023
Details:
CTX112 consists anti-CD19 allogeneic CRISPR-Cas9-engineered T cells, it is being investigated in subjects with relapsed or refractory B-cell malignancies.
Lead Product(s): CTX112
Therapeutic Area: Oncology Product Name: CTX112
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Exa-cel (Exagamglogene Autotemcel), formerly known as CTX001™, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with TDT or SCD.
Lead Product(s): Exagamglogene Autotemcel
Therapeutic Area: Genetic Disease Product Name: CTX001
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Vertex Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
